colorectal cancer Archives
Jun. 2, 2022—Two Vanderbilt researchers have received awards from the AGA Foundation, the charitable arm of the American Gastroenterological Association.
Mar. 9, 2022—Vanderbilt Wilson County Hospital's Lori Martin uses her own experiences to educate patients about the importance of early detection of colorectal cancer.
Feb. 14, 2022—Higher dietary intake of antioxidant compounds found in fruits, vegetables, teas and spices was associated with lower risk of colorectal cancer, and intake was lower among Black participants, potentially contributing to colorectal cancer health disparities.
Jan. 25, 2022—New research from Vanderbilt sets a comprehensive framework for addressing research challenges and patient needs for people under 50 with colorectal cancer.
Dec. 14, 2021—Vanderbilt research has revealed some of the mechanisms by which polyps develop into colorectal cancer, setting the framework for improved surveillance for the cancer utilizing precision medicine.
Nov. 11, 2021—A novel CRISPR screen developed by Vanderbilt researchers identified a promising new target for anti-inflammatory therapeutics.
May. 13, 2021—People with a high polygenic risk score for colorectal cancer could benefit more at preventing the disease by leading healthy lifestyles than those at lower genetic risk, according to a study by Vanderbilt researchers published in the April issue of The American Journal of Clinical Nutrition.
Nov. 23, 2020—Women diagnosed with early-onset colorectal cancer have a greater risk of dying from the disease depending upon their county of residence, according to a study published in Clinical and Translational Gastroenterology.
Nov. 18, 2020—Mariana Byndloss, DVM, PhD, assistant professor of Pathology, Microbiology and Immunology, has received a V Scholar Award to support her studies of the links between obesity, the gut microbiome and colorectal cancer.
Nov. 18, 2020—A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration is being tested in a phase 3 clinical trial at Vanderbilt-Ingram Cancer Center.